Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén Dec 15, 2022
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer Nov 30, 2022
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer Nov 15, 2022
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference Oct 26, 2022
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17 Oct 12, 2022
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027 Sep 29, 2022
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program Aug 23, 2022
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office Aug 16, 2022
